Jeanmarie Guenot is one of the most renowned personalities in the field of biotechnology and biopharmaceuticals and has an extensive experience of over two decades. Over the career spanning more than twenty years, Jeanmarie has worked with numerous companies in both public and private domain. At present, Jeanmarie serves as the President and Chief Executive Officer of Amphivena Therapeutics Inc, a firm that is focused on immune therapies research and finding effective diagnose for blood cancers. The company is headquartered in San Francisco, and even though it is under pre-clinical development stage, the firm aims to provide an efficient cure for hematological malignancies, blood cancer, and tumors.
Jeanmarie’s experience over the years has broadened her skills and expertise portfolio, which now includes pharmaceutical research and development, business development, project management, commercial product portfolio, alliance management, licensing, client management, venture capital, corporate development, merger and acquisitions, scientific collaborations, and more reported on amphivena.com. During her career span of over twenty years, Jeanmarie has had an opportunity to work in most of the major therapeutic areas. She did her Masters in Business Administration from University of Pennsylvania’s Wharton School of Business and Ph.D. from University of California, San Francisco.
Jeanmarie Guenot joined Hoffman-La Roche after completing her studies as a team leader and principal scientist, handling Preclinical research and development. After working for six years for Hoffman-La Roche, she joined Atlas Venture as an associate in the Life Sciences department, and it is where her business expertise flourished as she looked for lucrative biotech firms to invest in and acquire. After leaving Atlas Venture, Jeanmarie joined PDL BioPharma as Vice President of Corporate and Business Development and even started her company named Guenot LLC in 2008, which provided business consulting services in the biotechnology and pharmaceutical sector on BusinessWire.com.
Jeanmarie is also the founder of SKS Ocular, LLC, a biotechnology startup that aims at improving cancer therapies and finding an innovative cure for hematological malignancies, macular degeneration, and glaucoma. She has won many awards at https://www.takeda.com/news/2017/20170111_7659.html during her career span, which includes Deal of Distinction Award by Licensing Executives Society and Innovative Bio-Partnering Award by BioBusiness Network. Jeanmarie Guenot continues to be enterprising in the biotechnology sector to help take Amphivena Therapeutics collaborate, grow and expand, to achieve its mission of finding effective cancer therapies successfully.